Core Viewpoint - The article discusses a class action lawsuit against Cassava Sciences, Inc. (NASDAQ: SAVA) following the disappointing results of its Alzheimer's drug candidate, simufilam, which led to a significant drop in the company's stock price [2][4]. Group 1: Allegations and Stock Performance - The complaint alleges that defendants provided misleading information regarding simufilam's efficacy in treating Alzheimer's Disease, expressing confidence in its performance [2]. - On November 25, 2024, Cassava announced that simufilam failed to meet all primary, secondary, and exploratory endpoints in its Phase 3 "ReThink-ALZ" study, underperforming against a placebo [2]. - Following the announcement, Cassava's stock plummeted from $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024, marking a decline of approximately 83.76% in just one day [2]. Group 2: Next Steps for Shareholders - Shareholders who purchased SAVA shares during the specified class period (February 7, 2024, to November 24, 2024) are encouraged to register for potential lead plaintiff appointment, with a deadline set for February 10, 2025 [3][5]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [3].

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Cassava and certain of its offic ...

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 18, 2024 /PRNewswi ...

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ps ...

SAN DIEGO, Dec. 16, 2024 /PRNewswire/ -- Robbins LLP announces that a class action was filed on behalf of all investors who purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Invest ...

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form-2/?id=116401&from=4CLASS PERIOD: Februar ...

NEW YORK, Dec. 13, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025.So what: If you purchased Cassava securities during the C ...

Cassava Sciences’ (SAVA) stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study for Alzheimer’s disease (AD).SAVA releases top-line results from the ReThink-ALZ study, which evaluated simufilam in patients with mild-to-moderate AD. Treatment with the drug failed to achieve a significant reduction in cognitive or functional decline in AD patients when compared to placebo over a 52-week period, ...

Core Viewpoint - Cassava Sciences' stock experienced a significant decline after the company announced that its Phase 3 trial results for Simufilam, a treatment for Alzheimer's disease, did not meet primary endpoints, leading to a drop of over 80% in share price [2][8][16]. Company Update - Cassava Sciences reported that the topline results from the ReThink-ALZ study indicated that Simufilam did not show a significant reduction in cognitive or functional decline compared to placebo in patients with mild-to-moderate Alzheimer's disease [2][3]. - The CEO of Cassava Sciences, Rick Barry, described the trial results as "disappointing for patients and their families" [4]. Market Reaction - Following the announcement, shares of Cassava Sciences fell by 84.6%, trading at $4.06, marking a new 52-week low, with the previous trading range being $8.79 to $42.20 [16]. - Martin Shkreli, a notable figure in the pharmaceutical industry, had predicted the stock's decline and suggested that the stock could trade near its cash value levels of $2 to $3 per share [11][12]. Predictions and Commentary - Shkreli expressed confidence that the failure to meet the primary endpoint would make the stock an "easy short" and criticized the speculative nature of some investors in Cassava Sciences [10][11]. - Citron Research supported Shkreli's prediction, highlighting the challenges of shorting stocks like Cassava Sciences, which they described as having been a "clear fraud for years" [15].